We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study of Glyceryl Tri-(4-phenylbutyrate) Administered Orally as a Single Dose, and Twice Daily for Seven Consecutive Days to Subjects With Hepatic Impairment With Cirrhosis and to a Control Group

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00986895
First Posted: September 30, 2009
Last Update Posted: January 16, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborator:
Ucyclyd Pharma, Inc.
Information provided by:
Horizon Pharma Ireland, Ltd., Dublin Ireland
  Purpose
The purpose of this study is to determine the safety and tolerability of GT4P administered orally as a single dose, and twice daily for 7 consecutive days, to subjects with hepatic impairment with cirrhosis (Child-Pugh scores of A, B, or C) and to a gender matched and similar age control group with normal hepatic function.

Condition Intervention Phase
Hepatic Encephalopathy Urea Cycle Disorders Drug: HPN-100 Phase 1

Study Type: Interventional
Study Design: Masking: None (Open Label)
Primary Purpose: Treatment

Resource links provided by NLM:


Further study details as provided by Horizon Pharma Ireland, Ltd., Dublin Ireland:

Primary Outcome Measures:
  • The rate of adverse event

Enrollment: 32
Study Start Date: September 2006
Study Completion Date: June 2007
Intervention Details:
    Drug: HPN-100
    HPN-100 is a triglyceride that has a similar mechanism of action as NaPBA. It is a liquid with minimal taste and odor. HPN-100 is broken down to phenylbuteric acid (PBA). PBA is converted to phenylacetic acid (PAA) that is the active metabolite. Three teaspoons of HPN-100 (~17.4mL) delivers an equivalent amount of PBA to40 tablets of NaPBA.
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

Subjects were required to fulfill the following criteria in order to participate in the study:

Screening:

  • Males or females aged ≥ 18 years of age
  • Able to provide written informed consent before any study-related procedures, and ability, in the opinion of the Investigator, to comply with all the requirements of the study
  • Classification to one of the following:

    • current diagnosis of hepatic impairment with cirrhosis
    • healthy subject
  • Subjects with hepatic impairment with cirrhosis were classifiable to one of the following groups:

    • Child-Pugh score A
    • Child-Pugh score B
    • Child-Pugh score C
  • Subjects with hepatic impairment with cirrhosis who were on a therapeutic regimen of lactulose must have been on a stable dose for ≥ 30 days prior to screening
  • If female, a negative pregnancy test at screening and pre-dose on day 0, or a documented sterilization procedure; a female of child-bearing potential must have been using a medically approved birth control method and must have agreed to use the same method of contraception during the full course of the study (on pre-dose day 0 as well as at screening)
  • Weight within the range of 60-100 kg (at screening and pre-dose on day 0)
  • Willing to stop taking any medication that the Sponsor and the Investigator felt was not appropriate for use during the study, beginning 2 days before dosing and throughout the study

Exclusion Criteria:

Subjects who fulfilled any of the following criteria were excluded from the study:

Screening:

  • Clinically significant history or evidence of cardiovascular, respiratory, renal, gastrointestinal, endocrine, neurological, immunological, or psychiatric disorder(s), as determined by the Investigator
  • Serum sodium < 120 mEq/L
  • Serum creatinine ≥ 1.5 upper limit of normal
  • Potassium ≤ 3.5 mEq/L
  • Other laboratory values outside the normal range which were determined to be clinically significant by the Investigator
  • Significant illness within the last 14 days
  • Oral temperature > 38.5°C or < 36°C and/or a suspected site of active infection
  • Inflammatory bowel disease or malabsorption defined with steatorrhea
  • Active gastrointestinal bleeding, defined as melena, hematochezia, or hematemesis requiring hospitalization within the last 30 days
  • Use of probenecid, valproate, or corticosteroids within the last 24 hours
  • Use of any medication, other than those approved by the Sponsor and Investigator, in the last 48 hours
  • History of seizures within the last 72 hours
  • Positive drugs of abuse urine test
  • Positive alcohol breath test
  • Donation or loss of blood (500 mL or more) within the last 30 days
  • Donation or loss of plasma within the last 7 days
  • History of acquired immunodeficiency syndrome (AIDS) or determined human immunodeficiency virus (HIV) positive
  • Hepatitis B or C (HBV; HCV) positive (healthy volunteers only)
  • Use of any investigational drug within the last 30 days
  • Known hypersensitivity to sodium phenylbutyrate or similar drugs
  • Emergency hospitalization within the last 90 days
  • Intake of alcohol in the last 7 days

Pre-dose (days 0 and 7):

  • Significant illness or emergency hospitalization since the last study visit
  • Oral temperature > 38.5°C or < 36°C and/or a suspected site of active infection
  • Use of probenecid, valproate, or corticosteroids within the last 24 hours
  • Use of any non-approved medication (by the Sponsor/Investigator) within the 48 hours before dosing
  • History of seizures within the last 72 hours
  • Positive drugs of abuse urine test
  • Positive alcohol breath test
  • Donation or loss of blood (500 mL or more) or plasma since the last study visit
  • Use of any investigational drug since the last study visit
  • Intake of alcohol in the last 7 days
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00986895


Locations
Ukraine
National University of Pharmacy
Kharkiv, Ukraine, 61057
Department of General Surgery #2; Kharkiv State Medical University
Kharkiv, Ukraine, 61128
Sponsors and Collaborators
Horizon Pharma Ireland, Ltd., Dublin Ireland
Ucyclyd Pharma, Inc.
Investigators
Principal Investigator: Igor Zupanets, MD National University of Pharmacy
  More Information

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
ClinicalTrials.gov Identifier: NCT00986895     History of Changes
Other Study ID Numbers: UP 1204-002
First Submitted: September 15, 2009
First Posted: September 30, 2009
Last Update Posted: January 16, 2017
Last Verified: September 2009

Keywords provided by Horizon Pharma Ireland, Ltd., Dublin Ireland:
HPN-100
GT4P
Glyceryl tri-(4-phenylbutyrate)

Additional relevant MeSH terms:
Brain Diseases
Hepatic Encephalopathy
Urea Cycle Disorders, Inborn
Central Nervous System Diseases
Nervous System Diseases
Liver Failure
Hepatic Insufficiency
Liver Diseases
Digestive System Diseases
Brain Diseases, Metabolic
Metabolic Diseases
Brain Diseases, Metabolic, Inborn
Amino Acid Metabolism, Inborn Errors
Metabolism, Inborn Errors
Genetic Diseases, Inborn
4-phenylbutyric acid
Antineoplastic Agents